Show simple item record

dc.contributor.authorCecamore, Cristinaen
dc.contributor.authorMarsili, Manuelaen
dc.contributor.authorSalvatore, Robertaen
dc.contributor.authorTroiani, Robertoen
dc.contributor.authorD'Egidio, Mauriziaen
dc.contributor.authorTinari, Nicolaen
dc.contributor.authorPelliccia, Piernicolaen
dc.contributor.authorChiarelli, Francescoen
dc.contributor.authorMarcovecchio, Loredanaen
dc.contributor.authorBreda, Lucianaen
dc.date.accessioned2018-11-23T15:36:47Z
dc.date.available2018-11-23T15:36:47Z
dc.date.issued2018-07en
dc.identifier.issn1439-7595
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/285898
dc.description.abstractOBJECTIVES: To assess whether circulating levels of 90K glycoprotein are increased in children with juvenile idiopathic arthritis (JIA) at different stages of the disease, compared to healthy controls and to evaluate potential over time changes in its concentrations following treatment with the antitumor-necrosis factor (TNF) drug etanercept. METHODS: 90K glycoprotein, C-reactive protein, erythrocyte sedimentation rate, TNF, antinuclear antibodies, rheumatoid factor and the Juvenile Arthritis Disease Activity Score were assessed in 71 children: 23 with newly diagnosed JIA, 23 with established and active JIA and 25 healthy controls. Patients, eligible for anti-TNF treatment, underwent a similar clinical/laboratory assessment after 6- and 12-month etanercept therapy. RESULTS: At baseline, significant differences were found in 90K levels between the three study groups: JIA at onset (157.7 [131.4-241.5] μg/ml), JIA on treatment (90.0 [68.8-120.2] μg/ml) and control group (58.0 [44.5-79.0] μg/ml), (p for trend <.001), with the JIA at onset group showing the highest values. In the JIA on treatment group, following one-year etanercept treatment, a significant reduction in 90K was detected already at 6 months (74.3 [56.0-104.1] μg/ml p = .001) and a further decline was observed at 12 months (49.3 [46.0-67.6] μg/ml p < .001). CONCLUSION: Our study showed that 90K glycoprotein levels are increased in JIA children compared to healthy controls, suggesting a potential pathogenetic role in the JIA. Besides, 12 months of therapy with etanercept can reduce 90K levels.
dc.format.mediumPrint-Electronicen
dc.languageengen
dc.subjectHumansen
dc.subjectTumor Necrosis Factor-alphaen
dc.subjectMembrane Glycoproteinsen
dc.subjectAntirheumatic Agentsen
dc.subjectAntigens, Neoplasmen
dc.subjectCase-Control Studiesen
dc.subjectAdolescenten
dc.subjectChilden
dc.subjectChild, Preschoolen
dc.subjectFemaleen
dc.subjectMaleen
dc.subjectArthritis, Juvenileen
dc.subjectBiomarkersen
dc.subjectEtanercepten
dc.title90K immunostimulatory glycoprotein in children with juvenile idiopathic arthritis.en
dc.typeArticle
prism.endingPage641
prism.issueIdentifier4en
prism.publicationDate2018en
prism.publicationNameModern rheumatologyen
prism.startingPage637
prism.volume28en
dc.identifier.doi10.17863/CAM.22835
dcterms.dateAccepted2017-10-02en
rioxxterms.versionofrecord10.1080/14397595.2017.1397895en
rioxxterms.versionAM*
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2018-07en
dc.contributor.orcidTinari, Nicola [0000-0001-8449-5407]
dc.contributor.orcidMarcovecchio, Loredana [0000-0002-4415-316X]
dc.identifier.eissn1439-7609
rioxxterms.typeJournal Article/Reviewen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record